A single injection of a genetically modified herpes simplex virus can infiltrate glioblastoma — the most aggressive form of brain cancer — kill tumor cells, and recruit immune fighters deep into the tumor. In a phase 1 clinical trial of 41 patients with recurrent glioblastoma, the treatment led to longer survival compared to historical outcomes, with the strongest benefit in patients who already had antibodies against the virus.

The engineered virus can only replicate inside glioblastoma cells, not healthy tissue. Once inside a tumor cell, it destroys it, produces copies of itself, and spreads to neighboring cancer cells. This process simultaneously activates the immune system, drawing cytotoxic T cells into the tumor. Patients whose T cells were found closer to dying tumor cells survived significantly longer after treatment.

The findings, published March 20 in the journal Cell by researchers from Mass General Brigham and Dana-Farber Cancer Institute, represent a major step toward making immunotherapy viable for brain tumors, which have historically resisted immune-based treatments.